Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024

Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its third quarter 2024 earnings release and conference call for November 6, 2024. The financial results will be released after market close, followed by a conference call at 2:00 p.m. Pacific Time. Investors can access the call via toll-free number 877-407-0989 or international number 201-389-0921. The call will also be available through the company's website, with a replay accessible within 24 hours after the live conference.

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.

The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.

Company Information

Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.

Forward Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the prospective benefits of the acquisition of BAQSIMI®, including its potential for continued revenue growth, the success of our integration of BAQSIMI®, the transition of our pipeline towards branded products and biosimilars, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024. In particular, there can be no guarantee that the acquisition of BAQSIMI® will be beneficial to our business in the long term, that any event, change or other circumstance could cause the results of the acquisition and integration of BAQSIMI® into our product portfolio to differ from Amphastar's expectation, that all or any of the contingent consideration will be payable on the terms described herein or at all, or that Amphastar can reliably predict the impact of BAQSIMI® on its financial results or financial guidance. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact:

Bill Peters
Chief Financial Officer
(909) 476-3416

SOURCE: Amphastar Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

When will Amphastar Pharmaceuticals (AMPH) release Q3 2024 earnings?

Amphastar Pharmaceuticals will release its Q3 2024 earnings after market close on Wednesday, November 6, 2024.

What time is Amphastar's (AMPH) Q3 2024 earnings conference call?

Amphastar's Q3 2024 earnings conference call is scheduled for 2:00 p.m. Pacific Time on November 6, 2024.

How can investors access Amphastar's (AMPH) Q3 2024 earnings call?

Investors can access the call by dialing toll-free 877-407-0989 (US) or 201-389-0921 (international), or through the Investors page on www.amphastar.com.